• To evaluate the effect of the co-administration of CYP3A4 inducers on VELCADE pharmacokinetics. [ Time Frame: Pharmacokinetics will be calculated by non-compartmental analysis of the plasma concentration time data on Day 11 of Cycles 2 and 3. ] [ Designated as safety issue: No ]
  

Inclusion Criteria:

• Male or female of at least 18 years of age.
• Has documented relapsed or refractory multiple myeloma or NHL following prior anti-neoplastic treatment.
• Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; have a negative serum β-HCG or a negative urine pregnancy test at screening. (an alternative to oral contraceptives should be used if the patient is randomized to Arm B with rifampicin).
• Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study.
• Must be able to swallow capsules/tablets whole (without chewing, crushing, or opening).
• Agree to refrain from the use of any methylxanthine-containing products, including caffeine (e.g., chocolate bars or beverages, coffee, teas, or colas), on Day 11 of Cycles 2 and 3.
• Agree to refrain from the use of any products containing nicotine, alcohol, quinine, grapefruit juice, or Seville oranges from 7 days before the first administration of VELCADE through completion of the 72-hour PK blood sample collection (post Day 11 VELCADE dose) in Cycle 3.
• Karnofsky Performance Status (Attachment 1) ≥50 points.
• Resolution of reversible toxicities considered related to any prior antineoplastic therapies.

• The following laboratory values at screening:

  • AST ≤3x upper limit of normal(ULN)
  • ALT ≤3x ULN
  • total bilirubin ≤2x ULN
  • hemoglobin ≥9 g/dL
  • platelets ≥ 50x 109/L
  • absolute neutrophil count (ANC) ≥1000/μL
  • calculated creatinine clearance ≥20 mL/min (Attachment 10, Creatinine Clearance Calculation)
• Patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
• In order to participate in the optional PGx component of this study, patients (or their legally acceptable representative) must have signed the informed consent form for PGx research indicating willingness to participate in the PGx component of the study (where local regulations permit). Participation in the PGx component is not mandatory for participation in the study.

Exclusion Criteria:

• Diagnosis or treatment of a malignancy other than multiple myeloma or NHL within 1 year of randomization, or who have previously been diagnosed with a malignancy other than multiple myeloma or NHL and have any radiographic or biochemical marker evidence of malignancy.
• History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric, or metabolic disturbances.
• Known or suspected hypersensitivity or intolerance to rifampicin and/or other antibiotics, corticosteroids, boron or mannitol.
• Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3 (Section 6.2).
• Preplanned surgery or procedures that would interfere with the conduct of the study or major surgery within 2 weeks before randomization.

• History of disallowed therapies:

  • Prior treatment with VELCADE.
  • Any drugs or agents that inhibit (e.g., cimetidine, erythromycin, fluoxetine, ketoconazole, paroxetine) or induce (e.g., carbamazepine, glucocorticoids, phenobarbital, phenytoin, St. John's Wort) CYP2C19 or CYP3A4 within 28 days before the first administration of VELCADE.
  • Any exposure to rifampicin or corticosteroids within 28 days of screening.
  • Have received an investigational agent or used an investigational medical device within 28 days before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
• Female patient who is pregnant or breastfeeding.
• Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.